English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Prostate cancer is a multifocal disease in 76–87% of patients [1,4,8]. Typically, 3 separate foci of cancer are seen in a prostate which has been surgically removed, but there may be as many as twelve [1,4, 8]. Standard prostate biopsies cannot reliably detect these foci [7]. Ultrasound imaging, in expert hands, has a receiver operator characteristic curve of 0.6 in determining whether a region of the prostate contains cancer [3]. MRI is marginally better at detecting the separate intraprostatic foci and CT is completely ineffective for such imaging [7]. (MR spectropscopy shows great promise and is discussed in this issue of Cancer Biomarkers.) Therefore, in contrast to most

disease markers. section a, cancer biomarkers

Potential benefits of intra-prostatic cancer-specific imaging to guide therapy and monitor outcome in patients treated with radiation-based treatments for localized prostate cancer